COVID-19 therapeutics I: Initial clinical application studies, up-scaling and production of GMP material of the complement C5a inhibitor AON-D21 for proof-of-concept in COVID-19 patients (Accelerate-D21)
- Funded by Federal Ministry of Research, Technology and Space (BMFTR)
- Total publications:0 publications
Grant number: 16LW0006
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$6,216,270.65Funder
Federal Ministry of Research, Technology and Space (BMFTR)Research Location
GermanyLead Research Institution
Aptarion Biotech AGResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable